-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Downgrades Capricor Therapeutics to Neutral

Benzinga·07/30/2026 11:11:08
Listen to the news
HC Wainwright & Co. analyst Joseph Pantginis downgrades Capricor Therapeutics (NASDAQ:CAPR) from Buy to Neutral.